Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
[Management of adverse events associated with molecular targeted agents].

Hinyokika kiyo. Acta urologica Japonica

Fujisawa M, Sugimura Y.
PMID: 23254791
Hinyokika Kiyo. 2012 Nov;58(11):633.

In Japan, sorafenib and sunitinib, potential molecular targeted agents for advanced renal cell carcinoma, were approved in 2008. Currently, a total of four agents, including everolimus and temsirolimus in addition to these two agents, have been introduced into clinical...

Cite
Fujisawa M, Sugimura Y. [Management of adverse events associated with molecular targeted agents]. Hinyokika Kiyo. 2012;58(11):633
Fujisawa, M., & Sugimura, Y. (2012). [Management of adverse events associated with molecular targeted agents]. Hinyokika kiyo. Acta urologica Japonica, 58(11), 633.
Fujisawa, Masato, and Sugimura, Yoshiki. "[Management of adverse events associated with molecular targeted agents]." Hinyokika kiyo. Acta urologica Japonica vol. 58,11 (2012): 633.
Fujisawa M, Sugimura Y. [Management of adverse events associated with molecular targeted agents]. Hinyokika Kiyo. 2012 Nov;58(11):633. Japanese. PMID: 23254791.
Copy Download .nbib Format: NLM
Interactions between Drugs and Surgery in the Treatment of LUTS and Advanced Renal Cancer.

Current drug targets

Sountoulides P, Symeonidis EN, Pyrgidis N, Cindolo L.
PMID: 33267754
Curr Drug Targets. 2020;21(15):1512-1514. doi: 10.2174/138945012115201102115645.

No abstract available.

Cite
Sountoulides P, Symeonidis EN, Pyrgidis N, et al. Interactions between Drugs and Surgery in the Treatment of LUTS and Advanced Renal Cancer. Curr Drug Targets. 2020;21(15):1512-1514doi: 10.2174/138945012115201102115645.
Sountoulides, P., Symeonidis, E. N., Pyrgidis, N., & Cindolo, L. (2020). Interactions between Drugs and Surgery in the Treatment of LUTS and Advanced Renal Cancer. Current drug targets, 21(15), 1512-1514. https://doi.org/10.2174/138945012115201102115645
Sountoulides, Petros, et al. "Interactions between Drugs and Surgery in the Treatment of LUTS and Advanced Renal Cancer." Current drug targets vol. 21,15 (2020): 1512-1514. doi: https://doi.org/10.2174/138945012115201102115645
Sountoulides P, Symeonidis EN, Pyrgidis N, Cindolo L. Interactions between Drugs and Surgery in the Treatment of LUTS and Advanced Renal Cancer. Curr Drug Targets. 2020;21(15):1512-1514. doi: 10.2174/138945012115201102115645. PMID: 33267754.
Copy Download .nbib Format: NLM
Novel targets for refractory kidney cancer: Where are we heading?.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Sarkis J, Sarkis P, Alkassis M, Assaf J, Ghazi R.
PMID: 34162246
J Oncol Pharm Pract. 2021 Sep;27(6):1559-1561. doi: 10.1177/10781552211027216. Epub 2021 Jun 24.

No abstract available.

Cite
Sarkis J, Sarkis P, Alkassis M, et al. Novel targets for refractory kidney cancer: Where are we heading?. J Oncol Pharm Pract. 2021;27(6):1559-1561doi: 10.1177/10781552211027216.
Sarkis, J., Sarkis, P., Alkassis, M., Assaf, J., & Ghazi, R. (2021). Novel targets for refractory kidney cancer: Where are we heading?. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 27(6), 1559-1561. https://doi.org/10.1177/10781552211027216
Sarkis, Julien, et al. "Novel targets for refractory kidney cancer: Where are we heading?." Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners vol. 27,6 (2021): 1559-1561. doi: https://doi.org/10.1177/10781552211027216
Sarkis J, Sarkis P, Alkassis M, Assaf J, Ghazi R. Novel targets for refractory kidney cancer: Where are we heading?. J Oncol Pharm Pract. 2021 Sep;27(6):1559-1561. doi: 10.1177/10781552211027216. Epub 2021 Jun 24. PMID: 34162246.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries